The Endocrine Society, a global organization representing thousands of physicians and scientists specializing in hormone research and clinical care, has officially voiced its support for the introduction of the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act in the U.S. House of Representatives. This bipartisan legislative effort seeks to address the long-standing crisis of insulin affordability in the United States, a nation where the cost of this essential hormone has historically outpaced inflation and created significant barriers to care for millions of patients.
The bill was introduced by a diverse coalition of lawmakers, including Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Kim Schrier (D-WA), Rob Bresnahan (R-PA), and Angie Craig (D-MN). By bridging the partisan divide, the sponsors aim to codify protections that would limit out-of-pocket expenses for those with private insurance and establish critical support systems for the uninsured. The move follows similar legislative initiatives in the Senate, signaling a unified congressional push to tackle the high cost of chronic disease management.
Core Provisions of the INSULIN Act
The INSULIN Act is designed as a multi-pronged solution to the economic pressures facing diabetes patients. At its center is a provision that would cap out-of-pocket insulin costs at $35 per month for individuals covered by private insurance plans. This cap mirrors the protections already established for Medicare beneficiaries under the Inflation Reduction Act of 2022, effectively extending those same safeguards to the commercial insurance market.
Beyond the price cap, the legislation addresses the vulnerabilities of the uninsured population. Recognizing that those without coverage often face the highest "list prices" at the pharmacy counter, the bill proposes the creation of a national resource center and a dedicated hotline. These tools are intended to connect uninsured patients with existing pharmaceutical assistance programs, state-level subsidies, and clinical resources to ensure that no individual is forced to go without medication due to a lack of insurance.
Furthermore, the act includes measures to foster market competition. By promoting the development and approval of biosimilar insulin products, the legislation aims to break the market dominance of traditional brand-name manufacturers. Biosimilars, which are highly similar to already-approved biological products, offer a pathway to lower prices through increased supply and competitive bidding, a strategy that has successfully reduced costs in other sectors of the pharmaceutical industry.
The Medical Necessity of Affordable Insulin
For the Endocrine Society and its members, the introduction of this bill is not merely a matter of economic policy but a critical intervention in public health. Robert W. Lash, MD, the Chief Medical Officer of the Endocrine Society, emphasized the life-or-death nature of the medication. “For the millions of Americans who rely on insulin every day, no one should have to choose between paying for their medication and meeting other basic needs,” Lash stated.
Insulin is a hormone produced by the pancreas that allows the body to use sugar (glucose) from carbohydrates for energy or to store glucose for future use. For the estimated 2 million Americans living with type 1 diabetes, their bodies produce little to no insulin, making daily injections or pump infusions a permanent requirement for survival. For many of the millions more living with type 2 diabetes, insulin becomes a necessary component of their treatment plan when other medications and lifestyle changes are insufficient to manage blood glucose levels.
The Endocrine Society’s endorsement of the $35 cap aligns with its official "Insulin Access and Affordability Position Statement." This document, which serves as a roadmap for the organization’s advocacy efforts, argues that the current pricing structure in the United States is unsustainable and poses a direct threat to patient safety. The Society maintains that lowering the financial burden on patients is the most direct way to improve adherence to medical advice and prevent the catastrophic complications associated with unmanaged diabetes.
The Human Cost of High Prices: Data and Statistics
The introduction of the INSULIN Act comes at a time when the prevalence of diabetes in the United States has reached record highs. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 38.4 million people—or 11.6% of the U.S. population—have been diagnosed with diabetes. An additional 97.6 million adults have prediabetes, a condition that significantly increases the risk of developing type 2 diabetes.
The economic consequences of this epidemic are staggering. However, the most alarming data point cited by the Endocrine Society and health researchers is the rate of insulin rationing. A study published in the Annals of Internal Medicine revealed that in 2021, nearly one in five American adults with diabetes—totaling approximately 1.3 million people—resorted to rationing their insulin. Rationing involves skipping doses, taking less than the prescribed amount, or delaying the purchase of a refill to save money.
Medical experts warn that insulin rationing is a dangerous practice that can lead to acute and chronic health crises. Short-term consequences include diabetic ketoacidosis (DKA), a life-threatening condition where the blood becomes acidic due to a lack of insulin. Long-term effects of poor glucose control include permanent organ damage, such as kidney failure (nephropathy), blindness (retinopathy), nerve damage (neuropathy), and an increased risk of heart disease and stroke. By capping costs, the INSULIN Act seeks to eliminate the financial incentive for rationing, thereby reducing the burden on the emergency medical system and improving long-term health outcomes.
Chronology of Insulin Legislation and Advocacy
The path to the INSULIN Act has been marked by years of advocacy and incremental legislative successes. The timeline below illustrates the evolution of the movement to lower insulin prices:
- 1921: Insulin is discovered by Frederick Banting and Charles Best. They famously sold the patent for $1 to ensure the medication would be available to everyone who needed it.
- 1990s–2010s: The list price of insulin in the U.S. begins a steep climb, increasing by over 1,000% in some cases, despite the basic formula remaining largely the same.
- 2018–2020: Several states, led by Colorado, began passing their own laws to cap out-of-pocket insulin costs for residents with state-regulated insurance plans.
- 2021: The Endocrine Society releases its "Insulin Access and Affordability Position Statement," providing a clinical framework for federal price caps.
- 2022: The Inflation Reduction Act (IRA) is signed into law. It includes a $35 monthly cap on insulin for seniors on Medicare but does not include protections for the millions of Americans on private insurance or those without coverage.
- 2023: Major insulin manufacturers, including Eli Lilly, Novo Nordisk, and Sanofi, announce voluntary price cuts and $35 caps for many of their products following public and political pressure.
- 2024: The INSULIN Act is introduced in the House of Representatives to codify these protections into federal law, ensuring they are permanent and universal across all private insurance providers.
Market Dynamics and the Role of Biosimilars
A unique aspect of the INSULIN Act is its focus on biosimilars. Unlike traditional "generic" drugs, which are chemical copies of brand-name pills, insulin is a biological product made from living cells. This makes the manufacturing process more complex and the regulatory pathway for "generic" versions more difficult.
Biosimilars are biological products that are highly similar to an FDA-approved reference product. The INSULIN Act seeks to streamline the entry of these products into the market. By fostering a more robust biosimilar market, the bill addresses the underlying lack of competition that has allowed a small number of manufacturers to maintain high prices for decades. Increased competition is expected to drive down the "list price" of insulin, which would benefit not only the patients at the pharmacy counter but also the broader healthcare system by reducing the premiums paid by employers and insurers.
Analysis of Implications and Future Outlook
The introduction of the INSULIN Act carries significant implications for the U.S. healthcare landscape. If passed, the bill would represent one of the most substantial expansions of federal drug price regulation in recent history.
From a fiscal perspective, while the cap reduces out-of-pocket costs for patients, it may shift some costs to insurance providers. However, proponents argue that these costs are offset by the long-term savings associated with better disease management. Treating a patient for a single episode of diabetic ketoacidosis in an intensive care unit can cost tens of thousands of dollars—far more than the annual cost of providing affordable insulin.
Politically, the bipartisan nature of the bill is noteworthy. With sponsors from both parties, the legislation has a higher probability of moving through the committee process in a divided Congress. The involvement of Representatives like Mariannette Miller-Meeks, who is a physician, and Kim Schrier, a pediatrician, lends clinical credibility to the proposal, framing it as a common-sense healthcare solution rather than a purely partisan maneuver.
The Endocrine Society has pledged to continue its work with both the House and the Senate to ensure the legislation reaches the President’s desk. The organization’s leadership believes that the INSULIN Act is an essential step toward a future where healthcare is determined by medical need rather than financial status. As the bill moves forward, it will likely serve as a focal point for the broader debate over prescription drug pricing and the role of government in regulating the cost of lifesaving therapies.
In the interim, the Society continues to provide resources for clinicians and patients to navigate the current pricing environment, advocating for transparency in the pharmaceutical supply chain and support for research into next-generation diabetes treatments. The ultimate goal remains clear: ensuring that the discovery made by Banting and Best over a century ago remains accessible to every individual whose life depends on it.
